'Most Favored Nation' Drug Pricing Is An Idea Whose Time Has Come

Area of Science:

• Health Economics
• Pharmaceutical Policy

Background:

• The United States exhibits higher pharmaceutical prices compared to peer nations.
• This price disparity results in disproportionate financing of global pharmaceutical research and development (R&D) by the US.
• Initiatives to address this disparity, such as "Most Favored Nation" (MFN) drug pricing, have been proposed.

Purpose of the Study:

• To analyze the instruments available to the US administration for achieving drug price goals.
• To assess the potential impact of these policy tools on pharmaceutical investment and innovation.

Main Methods:

• Policy analysis of available instruments for drug price negotiation.
• Assessment of the economic implications for the pharmaceutical industry, focusing on R&D investment and innovation.

Main Results:

• The threat of MFN drug pricing has prompted behavioral changes in pharmaceutical firms and payers globally.
• MFN pricing is anticipated to reduce industry revenues available for R&D.
• Potential moderating factors for R&D impact include improved investment prioritization and enhanced efficiency in innovation.

Conclusions:

• While MFN drug pricing presents political and administrative challenges, its threat has driven industry adjustments.
• The policy is likely to decrease pharmaceutical R&D funding, but the extent of this impact is uncertain.
• Strategic improvements in R&D investment and innovation efficiency could mitigate negative consequences.